Initially developed for use with MSCs, our human platelet lysates have evolved into a platform technology that has been used with successful results with many other cell types and applications, including 2D and suspension cultures, as well as organoids.
Whatever your application may be, our hPL will best feed your growing cell needs!
Some examples of cell types grown with our hPLs are T cells, NK cells, tumor cells, endothelial cells, iPSCs, fibroblasts, hepatocytes and cardiomyocytes.
MSCs are a promising candidate for tissue engineering and regenerative medicine applications due to their capacity of self-renewal and multilineage differentiation, ease of isolation and ability to grow in vitro. Our platelet lysates have demonstrated an outstanding performance expanding MSCs for use in human therapy and are currently being used in hundreds of clinical trials.
Chimeric Antigen Receptor (CAR) expressing T-cells have demonstrated potent clinical efficacy in patients with hematological malignancies. There are several phase I clinical trials evaluating the use of CAR-T-cells for targeting of solid tumor-associated antigens. Some of the challenges found during production of CAR-T cells are the efficiency of T cell transduction to generate CAR-T cells, the expansion of T cells to clinically relevant numbers and the long term survival in vivo of the therapeutic cells. The use of human platelet lysate has demonstrated to aid in the transduction of primary T cells, as well as to improve T cell expansion and prolong in vivo survival of cells. Our platelet lysates, offer an improved performance in T cell expansion versus serum derived products, but also versus other platelet lysates on the market. PLTGold® and PLTGold®-GI efficiently promote T cell expansion, with higher cell yields and lower cell exhaustion rates.
Additionally, our hPLs are suitable for suspension culture of T cells, facilitating the potential large-scale expansion in suspension of allogeneic CAR-T cells.
All products available on the market to grow endothelial cells contain either FBS or Bovine Brain Extract (BBE), which make them less appropriate, or not appropriate at all, to grow cells that will be used in clinical applications. EndoGoTM XF supplemented with our human platelet lysates, in addition to being animal product free, promote endothelial cell growth in a more efficient way than other products available in the market.
MCLS has the license to a patent for the use of platelet lysate to grow human tumor cells. The properties of platelet lysate make it an ideal supplement to efficiently expand primary tumor cells used on research or in translational medicine.
“p53 pathway dysfunction is highly prevalent in acute myeloid leukemia independent of TP53 mutational status”
“Novel strategy for manufacturing autologous dendritic cell/allogeneic tumor lysate vaccines for glioblastoma”
“Phase I trial of adjuvant mature autologous dendritic cell / allogeneic tumor lysate vaccines in combination with temozolomide in newly diagnosed glioblastoma”
MCLS’s PLTMax® has been used successfully in several 3D matrices. Since PLTMax contains all the clotting factors present in platelets, PLTMax can additionally be used to generate gels containing high concentrations of growth factors that could potentially be used for 3D culture of cells.
“Hydrogel supplemented with human platelet lysate enhances multi-lineage differentiation of mesenchymal stem cells”
“Extracellular matrix protein production in human adipose-derived mesenchymal stem cells on three-dimensional polycaprolactone (PCL) scaffolds responds to GDF5 or FGF2”
“Preservation of epithelial progenitor cells from collagenase digested oral mucosa during ex vivo cultivation”
“Osteogenic potential of human adipose-tissue-derived mesenchymal stromal cells cultured on 3D-printed porous structured titanium”
“Serum-Free Medium and Mesenchymal Stromal Cells Enhance Functionality and Stabilize Integrity of Rat Hepatocyte Spheroids”